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Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible visual loss in elderly populations. In recent




tenance, and discontinuation of anti-VEGF therapies, as well as emerging treatment strategies and future directions in the ﬁeld.
1.Introduction
Despite the recent introduction of new therapeutic ap-
proaches, and an improved awareness of modiﬁable dis-
ease risk factors, age-related macular degeneration (AMD)
remains a leading cause of irreversible visual loss in elderly
populations [1]. In the neovascular form of this disorder,
severe visual loss commonly occurs as a result of the
invasion of abnormal blood vessels from the choroidal cir-
culation with damage to the overlying retina (choroidal
neovascularization (CNV)) [2]. In recent years, pharmac-
ological inhibition of this process, through blockade of
the proangiogenic glycoprotein, vascular endothelial growth
factor (VEGF), has oﬀered the ﬁrst opportunity to improve
visual outcomes in patients diagnosed with this disorder [3].
In 2006, the results of the MARINA and ANCHOR
studies demonstrated that inhibition of VEGF by frequent
treatment with ranibizumab (Lucentis, Genentech, Inc.,
South San Francisco, CA) could lead to signiﬁcant visual
improvementinpatientswithneovascularAMD[4,5].How-
ever, while these pivotal clinical trials were still underway,
Rosenfeld et al. provided evidence that an agent designed
for treatment of colorectal cancer—bevacizumab (Avastin,
Genentech)—could also lead to signiﬁcant visual gains, but
at a substantially lower cost [6]. Consequently, bevacizumab
was quickly adopted for the treatment of neovascular AMD
by clinicians worldwide [7–9].
The widespread adoption of bevacizumab for the treat-
ment of neovascular AMD occurred in the absence of formal
guidelines from clinical trials; as a result, clinicians had
limited evidence for their initial eﬀorts at followup and
retreatment [10, 11]. “As required” retreatment strategies,
based on the assessment of disease activity using optical
coherence tomography (OCT), thus evolved, and their suc-
cess quickly led to their adoption for use with ranibizumab
[12]. While variable retreatment regimens oﬀer a number
of potential advantages, they place a greater onus on the
clinicianforaccurate,andconsistent,clinicalassessmentover
extended time periods—an obligation made diﬃcult with
the rapid evolution of retinal imaging techniques and the
proliferation of treatment strategies.
In this paper, we address these concerns by providing
recommendations on how bevacizumab and ranibizumab
may be best applied in current clinical practice. We begin2 Journal of Ophthalmology
by providing an overview of bevacizumab and ranibizumab,
with an emphasis on pharmacology and eﬃcacy. We next
review current guidelines for the initiation, maintenance,
and discontinuation of anti-VEGF therapies. We conclude
with a review of emerging treatment strategies and future
directions in the ﬁeld.
2.Ranibizumab
2.1. Pharmacology. Ranibizumab (formerly known as rhu-
FAb V2) is an antibody fragment that binds and inhibits all
isoforms of VEGF [13]. It is a chimeric molecule, consisting
ofanantigen-bindingmurinecomponent,andanonbinding
human component that serves to make it less antigenic.
Ranibizumab was developed by alteration of bevacizumab,
a humanized version of a murine monoclonal antibody
ﬁrst derived in 1996 (the decision to alter bevacizumab in
this manner was driven by preclinical studies suggesting
that a full-size antibody would be unable to penetrate
the retina) [13]. Substitution of targeted amino acids was
also performed in a bid to maximize the binding aﬃnity
of ranibizumab for VEGF, in the hope that this change
would lead to improved outcomes (the VEGF binding
aﬃnity of ranibizumab is approximately 100 times that of
bevacizumab) [13].
Intravitreously administered ranibizumab is thought to
exit the vitreous cavity via one of two pathways: poste-
riorly via retinal penetration and then drainage into the
choroidal vasculature or anteriorly through the aqueous
drainage route [14]. Knowledge of the vitreous half-life is
an important consideration when optimizing retreatment
frequencies, whereas serum concentrations are an important
factor with respect to systemic adverse eﬀects (e.g., stroke).
The pharmacokinetics of ranibizumab, after intravitreous
administration, have thus been studied both in animal
models and in human trials [15–17]. In animal studies,
ranibizumab is cleared from the vitreous with a half-life
of approximately three days. After reaching a maximum
at approximately one day, the serum concentration of
ranibizumab declines in parallel with this. In human studies,
following monthly intravitreous ranibizumab administra-
tion, maximum serum concentrations were dose depen-
dent but low (0.3ng/mL to 2.36ng/mL—levels thought
to be below the concentrations necessary for reduction
in biological activity of VEGF by 50%). Based on neo-
vascular AMD population pharmacokinetic analysis, max-
imum serum concentrations of 1.5ng/mL are predicted
to be reached at approximately one day after monthly
intravitreous administration of 0.5mg of ranibizumab
(in humans, serum ranibizumab concentrations are pre-
dicted to be approximately 90,000-fold lower than vitre-
ous concentrations). Thus, based on its elimination from
serum, the estimated average vitreous elimination half-life
was approximately nine days (http://www.gene.com/gene/
products/information/pdf/lucentis-prescribing.pdf).
2.2. Eﬃcacy. In 2006, ranibizumab was licensed for use in
the United States following publication of the MARINA and
ANCHOR studies [4, 5].
In the MARINA trial, patients with either “minimally
classic” or “occult” angiographic leakage patterns were
randomized to receive monthly injections of intravitreous
ranibizumab (0.3mg or 0.5mg) or monthly sham injections
[5]. At the 12-month point of this study, visual acuity had
improved by 15 or more letters in 24.8% of the 0.3mg group
and 33.8% of the 0.5mg group (as compared with only
5.0% of the sham-injection group). Furthermore, patients
receiving ranibizumab, on average, demonstrated increases
in visual acuity (6.5 letters in the 0.3mg group and 7.2 letters
in the 0.5mg group), while those receiving sham therapy,
on average, demonstrated losses (10.4 letters in the sham-
injection group). In addition, the vast majority of patients
receiving ranibizumab avoided moderate visual loss (94.5%
of the group receiving 0.3mg of ranibizumab and 94.6%
of those receiving 0.5mg), while only 62.2% of the control
group managed to do so. Subsequently, at the 24-month
conclusion of the study, the visual beneﬁts gained from the
ranibizumab groups were maintained.
In the ANCHOR trial, patients with “predominantly
classic” angiographic leakage patterns were randomized
to receive either 24 monthly intravitreous injections of
ranibizumab (either 0.3mg or 0.5mg) or photodynamic
therapy with verteporﬁn [4]. Visual acuity improved by 15
letters or more in 35.7% of the 0.3mg group and 40.3% of
the 0.5mg group (as compared with 5.6% of the verteporﬁn
group).AsintheMARINAtrial,thosereceivingranibizumab
also demonstrated a mean increase in visual acuity (8.5
letters in the 0.3mg group and 11.3 letters in the 0.5mg
group), while those in the control group experienced a mean
decrease (9.5 letters in the verteporﬁn group). Similarly,
94.3% of those given 0.3mg of ranibizumab and 96.4% of
those given 0.5mg avoided further moderate visual loss (as
compared with 64.3% of those in the verteporﬁn group).
Subgroup analyses were also performed in both the
MARINA and ANCHOR studies and demonstrated the
importance of prompt diagnosis and treatment in patients
with neovascular AMD—that is, younger patients, with
smaller lesions, and relatively preserved visual acuities,
tended to have the best visual outcomes [18, 19]. Conversely,
patients with moderate visual loss after monthly treatment
with ranibizumab were found to have a higher concentration
of atrophic scarring and pigmentary abnormalities, suggest-
ing the need for additional strategies aimed at photoreceptor
and retinal pigment epithelium (RPE) cell preservation [20].
3.Bevacizumab
3.1. Pharmacology. Bevacizumab is a full-length monoclonal
antibody, ﬁrst derived from a murine source and prepared
for intravenous administration, which binds to and inhibits
the biologic activity of all isoforms of VEGF [13, 14].
Bevacizumab was originally developed and approved for the
treatment of metastatic colorectal cancer, but it is now also
used in the treatment of nonsmall cell lung cancer and in
patients with metastatic breast cancer [21]. The results of
preliminary studies suggested that bevacizumab, due to its
large size, would not be fully distributed within the retinal
layers—hence, the development of an antibody fragment,Journal of Ophthalmology 3
ranibizumab,forthetreatmentofneovascularAMD[13,14].
Furthermore, the longer half-life of a complete antibody,
versus an antibody fragment, raised concerns regarding
systemic toxicity in patients requiring long-term anti-VEGF
blockade.
In comparison with ranibizumab, less is known about
the intraocular pharmacokinetics of bevacizumab. In a
recent study by Bakri et al., a rabbit model was used to
study the vitreous half-life and serum concentrations after
intravitreous injection of 1.25mg of bevacizumab [22]. In
this study, the vitreous half-life was found to be longer than
ranibizumab at 4.32 days (versus 2.88 days for ranibizumab),
and the maximum serum concentrations were reached
after eight days. Of note, small amounts of bevacizumab
were detected in the vitreous of the fellow, uninjected
eye. In an animal study (albino rabbits) by Shahar et al.,
confocal immunohistochemistry was used to demonstrate
full thickness retinal penetration 24 hours after intravitreous
injection (and the essential absence of bevacizumab) by
four weeks after injection [23]. In a more recent study
performed in humans, an aqueous half-life of 9.82 days was
found after intravitreous injection of 1.5mg of bevacizumab
[24].
3.2. Eﬃcacy. In 2005, Rosenfeld et al. reported that intravit-
reous administration of bevacizumab led to rapid resolution
of abnormalities on OCT in a patient with neovascular AMD
[6]. A large number of oﬀ-label, short-term, uncontrolled,
retrospective case series have since evaluated the eﬃcacy
of intravitreous bevacizumab in neovascular AMD—until
recently, however, no evidence from randomized controlled
clinical trials existed for its use [25].
In 2010, the results of the ABC trial provided the ﬁrst
level I evidence for the eﬃcacy of intravitreous bevacizumab
in neovascular AMD [26, 27]. In this prospective, double-
masked, multicenter, randomized, controlled trial, 32% of
patients treated with bevacizumab gained 15 or more letters
from baseline visual acuity. More than 45% of patients
treated with bevacizumab improved 10 or more letters, a
threshold that exceeds the variability of the measurement
of visual acuity and represents the proportion of patients
recovering vision. In addition, 91% of patients receiving
bevacizumab lost fewer than 15 letters of visual acuity from
baseline (i.e., avoided moderate visual loss). Finally, mean
visual acuity increased by 7.0 letters in the bevacizumab
group with a median of seven injections over a 54-week
period.
In 2011, the results of the CATT study provided further
level I evidence for the eﬃcacy of bevacizumab in the treat-
ment of neovascular AMD [28]. In this study, patients with
neovascular AMD were randomized to receive intravitreous
injections of ranibizumab or bevacizumab on either a ﬁxed,
monthlyschedule,oronan“asrequired”basis.Theresultsof
this study suggest that bevacizumab administered monthly
is equivalent to ranibizumab administered monthly (mean
visual acuity increase of 8.0 letters and 8.5 letters, resp.),
and that bevacizumab administered as needed is equivalent
to ranibizumab administered as needed (mean visual acuity
increase of 5.9 letters and 6.8 letters, resp.).
4. Diagnosis and Initiationof Therapy
4.1. Visual Acuity and Clinical Examination. Assessment of
patientswithsuspectedneovascularAMDbeginswithacare-
fulhistory(especiallythenatureanddurationofsymptoms),
slit-lamp biomicroscopy, and measurement of visual acuity.
Accurateassessmentofvisualacuityisessential—inthiscon-
text, logMAR (logarithm of the minimum angle of resolu-
tion) visual acuities obtained using Early Treatment Diabetic
Retinopathy Study (ETDRS) charts are preferable to Snellen
visual acuities (in patients with AMD, Snellen visual acuities
are consistently lower (worse) than ETDRS visual acuities)
[29]. This factor may be of critical importance in healthcare
systems where anti-VEGF therapy can only be provided
according to certain prespeciﬁed criteria. For example, in the
United Kingdom, the NICE (National Institute for Health-
care and Clinical Excellence) guidelines state that patients
with logMAR visual acuity ranging between 0.3 (Snellen,
6/12) and 1.2 (Snellen, 6/96) are eligible for treatment [30].
4.2. Fluorescein Angiography. Fluorescein angiography is an
important component in the initial diagnosis of neovascular
AMD and should be carried out in all patients except
where precluded by allergy or other systemic considerations
[31]. Fluorescein angiography is of particular value for
the assessment of CNV lesion location, classiﬁcation, and
size. Determination of CNV location is critical: for well-
demarcated lesions located extrafoveally, the use of laser
photocoagulation may allow the patient to avoid the need for
monthly intravitreous injections over an extended follow-up
period [32]. Consideration of angiographic lesion classiﬁca-
tion is also important when determining whether to initiate
treatment. In lesions classiﬁed as “occult” on ﬂuorescein
angiography, the decision to treat can often be deferred if
there is no evidence of disease progression, with many such
lesions remaining quiescent for extended time periods [5].
Finally, evaluation of lesion size prior to treatment may
provide a useful baseline parameter against which future
lesion growth can be assessed, particularly in diﬃcult cases
where repeat ﬂuorescein angiography is required [25].
Fluoresceinangiographymayalsobeusefulfortheexclu-
sion of other macular disease that can mimic the features of
neovascular AMD, such as retinal macroaneurysms resulting
in submacular haemorrhage, central serous chorioretinopa-
thy resulting in subretinal and sub-RPE ﬂuid, and pattern
dystrophieswherethereisprogressivestaining ofvitelliform-
like material [25]. Fluorescein angiography can also assist
in the diagnosis of conditions where CNV is present but
due to etiologies other than AMD, for example, angioid
streaks, pathologic myopia, inﬂammatory disorders, trauma
[25]. Non-AMD CNV may respond diﬀerently to anti-
VEGF blockade (e.g., requiring fewer treatments) and, in
some case, may beneﬁt from alternative or supplementary
treatment regimens (e.g., systemic immunosuppression for
inﬂammatory CNV).
4.3. Indocyanine Green Angiography. In many Asian coun-
tries, where the prevalence of polypoidal choroidal vascu-
lopathy is high, indocyanine green angiography (ICGA) is4 Journal of Ophthalmology
an important part of baseline investigations in suspected
cases of neovascular AMD [33, 34]. While this is not yet
the standard-of-care in most Western countries, baseline
ICGA may still be useful in selected cases, particularly in
the context of substantial submacular haemorrhage, where it
may be useful for determining the presence or extent of any
underlying CNV lesion [35].
4.4. Signs of Disease Activity. If clinical examination and
imaging studies conﬁrm the presence of subfoveal CNV
secondary to AMD, and the disease appears active, treatment
with intravitreous ranibizumab or bevacizumab should be
initiated without delay (treatment delay has been shown to
have detrimental eﬀects on ﬁnal visual outcomes) [36, 37].
In neovascular AMD, these signs of disease activity include
(1) deterioration in visual acuity
(2) evidence of CNV leakage on ﬂuorescein angiography
(3) abnormal retinal thickness on OCT, with evidence of
intraretinal, subretinal, or sub-RPE ﬂuid
(4) presence/recurrence of intraretinal or subretinal
haemorrhage.
In patients presenting with bilateral active CNV lesions, it
may be reasonable to treat both eyes in a single setting or
within a short time period of each other, providing asepsis is
ensured [30, 38].
4.5. Other Clinical Scenarios. Patients with neovascular
AMD often present with disease features that were not eval-
uated in—or were speciﬁcally excluded from—randomized
clinical trials. For example, ranibizumab or bevacizumab
therapy may be of beneﬁt in patients with predominantly
hemorrhagic lesions, [39, 40] although such lesions were
speciﬁcally excluded from the pivotal clinical trials of
ranibizumab and bevacizumab. The prognosis may be
guarded in such patients, however, particularly if there is an
underlyingRPEtear[41]oriftheaccumulatedbloodhashad
at o x i ce ﬀect on the RPE and photoreceptors [42]. In addi-
tion, some patients with predominantly hemorrhagic CNV
lesions may beneﬁt from surgical management approaches,
for example, pneumatic displacement of the haemorrhage,
with or without the use of tissue plasminogen activator
[43].
Caution is also required in treating CNV lesions where
greater than 50% of the lesion is made up of serous pigment
epithelium detachment—such lesions may be at greater risk
for development of RPE tears [44]. Other lesions falling
outside clinical trial treatment criteria include those with
advanced subretinal ﬁbrosis or geographic atrophy involving
the foveal center; a trial of bevacizumab or ranibizumab may
be indicated but, in general, such cases are unlikely to beneﬁt
from continued treatment. Similarly, patients with initial
visual acuities worse than 20/320 were excluded from most
clinical trials and are less likely to beneﬁt from treatment.
Patients with initial visual acuities better than 20/40 are
also not typically evaluated in clinical trials of neovascular
AMD—treatment of such patients should, however, still be
considered in the case of active subfoveal or juxtafoveal
disease [45].
Patients with neovascular AMD commonly present with
signiﬁcant ocular comorbidity [30, 38]. In patients with
elevated intraocular pressure, even in cases where it exceeds
30mmofHg,initiationofantiangiogenictherapyshouldnot
bedelayed,providingantiglaucomatherapiescanbeinitiated
concomitantly. In patients with visually signiﬁcant cataracts,
it is also preferable that CNV activity is controlled prior to
any surgical procedure for the removal of cataract.
As the patient population aﬀected by neovascular AMD
is, by deﬁnition, elderly, the presence of any signiﬁcant
systemic comorbidity is also an important consideration
[46]. Bevacizumab was originally developed and approved
for the treatment of metastatic colorectal cancer and, in
this context, was associated with increased incidences of
hypertension, bleeding, and thromboembolic events [21].
While the MARINA and ANCHOR trials did not show any
diﬀerence in the incidence of serious adverse eﬀects between
treatment and control groups, [4, 5]. an interim analysis
from the SAILOR study showed a trend for an increase in
the incidence of stroke in the group treated with 0.5mg
of ranibizumab [47, 48]. Moreover, the incidence of stroke
was higher with preexisting risk factors, in particular a
previous history of stroke or arrhythmia. These ﬁndings,
and recent studies demonstrating both the eﬀects of intrav-
itreous bevacizumab on systemic VEGF levels [49]a n da n
association between AMD itself and higher risk of stroke
[50], suggest that extra discussion may be warranted prior to




5.1. Fixed Retreatment—Monthly versus Quarterly. In the
MARINA and ANCHOR studies of ranibizumab, monthly
treatments were provided over a two-year period—each
patient thus received a total of 24 injections [4, 5]. Other
large clinical trials have since evaluated the beneﬁts of
ranibizumab in less-frequent retreatment regimens, for
example, the PIER, EXCITE, and SAILOR studies [51–
53]. In these studies, patients were initially treated with
three injections of ranibizumab on a monthly basis—often
termed the loading phase—with subsequent retreatment on
a quarterly basis.
The results of the PIER study, while being generally
positive, failed to equal those of the MARINA and ANCHOR
trials [51, 52]. Speciﬁcally, patients receiving quarterly
r e t r e a t m e n t sh a dl e s sm e a ng a i ni nv i s u a la c u i t y ,a n da
smaller percentage of patients experienced 15 or more letters
of visual gain. Furthermore, the initial visual gain attained
during the loading phase was not maintained during the
remainder of the study.
In the EXCITE study, monthly maintenance therapy
with 0.3mg of intravitreous ranibizumab was compared
to the PIER study quarterly regimen (0.3mg and 0.5mg)
reduced-frequency ﬁxed-dose schedule, with the resultsJournal of Ophthalmology 5
again suggesting better mean visual acuity gains in patients
receiving monthly retreatment [53]. Finally, the SAILOR
studyevaluatedaloadingphaseofthreeconsecutivemonthly
injections followed by quarterly monitoring with retreat-
ment determined by physician discretion (Cohort 2) or by
visual acuity and OCT criteria (Cohort 1)—the results of
this study provided further conﬁrmation that quarterly visits
areinsuﬃcientforoptimalmonitoringofdiseaseprogression
[54].
5.2. “As-Required” Retreatment. Despite the strong evidence
from the MARINA and ANCHOR studies, ﬁxed, monthly
ranibizumab retreatment regimens have not been widely
adopted [5]. While a variety of retreatment protocols are in
use, the dosing schedule described in the PrONTO study is
perhaps the most widely used in clinical setting [12].
In the PrONTO study, an OCT-guided variable dos-
ing regimen was used for the treatment of neovascular
AMD with ranibizumab [12]. Subjects enrolled in this
small,single-centerstudyreceivedthreeconsecutivemonthly
intravitreous injections of ranibizumab. After this loading
phase, ranibizumab retreatment was performed, in large
part, based on OCT criteria: a loss of ﬁve letters of visual
acuity in conjunction with intraretinal ﬂuid on OCT or an
increase of OCT central retinal thickness of at least 100µm,
being indications for retreatment. Other criteria used to
trigger retreatment consisted of new-onset haemorrhage or
new “classic” CNV (although, for the latter, ﬂuorescein
angiography was only required at followup in cases of
signiﬁcant or unexplained visual loss). In the second year
of the study, the retreatment criteria were modiﬁed so that
any evidence of recurrent intraretinal, subretinal, or sub-
RPE ﬂuid was grounds for retreatment [55]. The results of
this study provided evidence that “as-required” retreatment
regimens could be a viable approach when administering
ranibizumab in the treatment of neovascular AMD. In the
ﬁrst 12 months of the PrONTO study, participants received
an average of 5.6 intravitreous injections of ranibizumab. In
contrast, the results from a recent retrospective case series
[56], and from a drug and disease model [57], suggest that
approximately eight injections may be required, on average,
in the ﬁrst year of individualized retreatment.
The ABC trial, which provided the ﬁrst level I evi-
dence for the eﬃcacy of bevacizumab in the treatment
of neovascular AMD, was also based on an as-required
retreatment strategy [27]. In the ABC trial, after an initial
loading phase, the criteria for retreatment were persistence
or recurrence of subretinal ﬂuid on OCT, new haemorrhage,
new classic CNV, or a drop of vision by ﬁve or more
letters with new intraretinal ﬂuid on OCT. If there was
persistent intraretinal ﬂuid after two consecutive treatments,
then treatment was withheld assuming that other criteria for
retreatment were not triggered. Of note, patients received
retreatment, when necessary, at six weekly intervals (in
the PrONTO study, monthly followup, and retreatment
intervals were used). Using this retreatment approach, the
results of the ABC trial demonstrated that, after 54 weeks,
32% of those receiving bevacizumab achieved 15 or more
letters of visual gain—results comparable to those reported
for ﬁxed retreatment in the MARINA and ANCHOR
studies.
More recently, in the large, multicenter, CATT study, the
eﬃcacies of ranibizumab and bevacizumab were compared
using both ﬁxed, monthly retreatment, and as-required
retreatment strategies [28]. In the as-required retreatment
groups, the triggers for retreatment included ﬂuid on OCT
new or persistent haemorrhage, decreased visual acuity, or
dye leakage or increased lesion size on ﬂuorescein angiogra-
phy (again, ﬂuorescein angiography was only performed at
the discretion of the treating physician to aid in retreatment
decisions). In the CATT study, ranibizumab administered
monthly led to a gain of 8.5 letters at 12 months, whereas
ranibizumab administered as needed led to a gain of 6.8
letters. Similarly, bevacizumab administered monthly led to
a gain of 8.0 letters at 12 months, whereas bevacizumab
administered as needed led to a gain of 5.9 letters. Although
ﬁxed monthly retreatment led to greater mean visual acuity
gain, the diﬀerences were not signiﬁcant for the ranibizumab
groups and were inconclusive for the bevacizumab groups.
While the results from the ABC and CATT reports are
encouraging, both studies have only reported their ﬁndings
after approximately one year of followup. For longer follow-
ups, the results of the SUSTAIN and HORIZON trials have
suggested that substantial visual acuity gain is less likely
with retreatments that occur less than monthly, whether
t h e yb ed e t e r m i n e do nar e d u c e df r e q u e n c y ,ﬁ x e dd o s i n g
schedule, or inﬂuenced by imaging parameters such as OCT
or ﬂuorescein angiography [25, 28]. For example, the HORI-
ZON extension study demonstrated that one year after entry
into the study, when monthly treatments were replaced by
physician-determined retreatment decisions median visual
acuity decreased by ﬁve letters after one year and by a further
three letters after two years [25].
5.3. “Treat and Extend”. Although there is an absence
of evidence from clinical trials, a wide variety of other
retreatment regimens—often tailored to healthcare system-
speciﬁc logistical factors—have been adopted worldwide
[58]. In an attempt to minimize both the number of
injections required, and the number of hospital visits, a
“treatandextend”approachhasrecentlybeendescribed[59–
61]. In this method, monthly injections with ranibizumab
are provided until all signs of exudation have resolved as
seen with OCT. The treatment interval is then sequentially
lengthened by one to two weeks as long as there are no
signs of recurrent exudation. When recurrent exudation
is detected on a follow-up visit, the treatment interval is
reduced to the prior interval. Thus, treatment is rendered
at every visit but the time between visits is individualized
based on a given patient’s response to treatment. To date, this
approach has only been evaluated in the context of single-
center retrospective studies.
5.4. Neovascular AMD “Refractory” to Treatment. The ﬁnd-
ings of the PrONTO study suggest that 70% of patients
treated with intravitreous ranibizumab will have resolu-
tion of macular edema within one month of their ﬁrst
injection (as demonstrated using OCT); similarly, more6 Journal of Ophthalmology
than 90% of patients will have resolution of all ﬂuid
following a loading phase of three consecutive monthly
injections [12]. In a small minority of patients, however,
the anatomical signs of ﬂuid exudation (and hence dis-
ease activity) appear refractory to anti-VEGF therapy—
such patients may have polypoidal choroidal vasculopathy,
a disease variant best detected using indocyanine green
angiography, and common in Asians and African Americans
[62,63].Thetreatmentofpolypoidalchoroidalvasculopathy
has not yet been adequately addressed in clinical trials,
althoughmanyauthoritiesrecommendtheuseofanti-VEGF
therapy in combination with photodynamic therapy with
verteporﬁn. The results of the EVEREST study—a phase
IV clinical trial investigating the use of ranibizumab in
PCV—should provide further clariﬁcation regarding this
[25].
5.5. Precision and Safety of Repeated Intravitreous Injection.
Repeated intravitreous injection of ranibizumab and beva-
cizumab,overextendedtimeperiods,hasbeendemonstrated
to result in a low incidence of serious ocular adverse events.
In the CATT study, endophthalmitis developed after only
two of 5449 injections (0.04%) in 599 patients treated with
ranibizumab, and after only four of 5508 injections (0.07%)
in 586 patients treated with bevacizumab. Uveitis, retinal
detachment, retinal vascular occlusion or embolism, retinal
tear, and vitreous hemorrhage each also occurred in less
than 1% of patients. Eﬀorts are underway to reduce further
the incidence of these events, with studies evaluating the
eﬀect of needle type and injection technique on patient
pain levels, vitreal reﬂux, and ocular complications [64].
Other studies have demonstrated the presence of particulate
contaminates—with the risk of inﬂammatory reaction—
followingthepreparationofbevacizumabforintraocularuse
[14, 65]; such ﬁndings emphasize the need for implemen-
tation of stringent protocols when preparing these drugs.
Finally, a number of studies have demonstrated signiﬁ-
cant variations in the accuracy, precision, and repeatability
of intravitreal dosages, underlining the need for care in
drawing up and administering therapeutics Intravitreously
[66].
6. Discontinuation of Therapy
Although there is a considerable body of work documenting
the natural history of untreated neovascular AMD, the
duration of disease activity in patients receiving anti-VEGF
therapy is less clear [48]. Similarly, the frequency and likeli-
hoodofdiseaserecurrenceremainsunknown.Evidencefrom
the HORIZON extension study suggests that neovascular
AMD may remain active for a number of years—in this
study, 61% of patients treated with monthly ranibizumab
over a two-year period required further treatment in the
third year [25, 48]. Thus, careful monitoring of patients
with neovascular AMD, for extended time periods, is
mandatory.
On occasion, discontinuation of treatment for situations
other than lack of disease activity may also be required [38,
48]. For example, treatment may be deferred or terminated
in situations where further visual improvement appears
unlikely, for example, severe RPE tears involving the foveal
center, or in the context of signiﬁcant coexisting geographic
atrophy or subfoveal scar formation. Limited evidence
exists evaluating the beneﬁts of continued treatment with
ranibizumab in the case of RPE tears (although no data
suggest that such an approach should be contraindicated).
7. Emerging Treatment Strategies and
FutureDirections
7.1. Anti-VEGF Tachyphylaxis. Recent evidence suggests
that, while treatment with ranibizumab leads to rapid early
reductions in retinal thickness, this eﬀect may be attenuated
over time. This attenuation is suggestive of tachyphylaxis
(other studies have reported similar ﬁndings with regard to
bevacizumab) [67–72]. A number of strategies may prove
useful in dealing with such phenomenon. Anecdotal evi-
dence suggests that patients exhibiting signs of ranibizumab
tachyphylaxis may beneﬁt from being switched to beva-
cizumab (and vice versa). Similarly, patients with anatomical
evidence of tachyphylaxis may beneﬁt from the use of
“treatment holidays” or the use of ranibizumab at higher
doses. In the ongoing HARBOR trial, OCT-guided therapy
is being used to compare the typical dose of ranibizumab
(0.5mg) with an increased dose (2.0mg). Increased doses of
bevacizumab are also under investigation [25, 48].
7.2. Role of Combination Therapy. A number of authors have
recently suggested that, in neovascular AMD, combining
treatments with diﬀerent mechanisms of action may result
in synergistic beneﬁts, including better visual outcomes,
reducedfrequencyoftreatments,lowerriskofadverseevents,
and decreased likelihood of “escape” (i.e., the development
of alternative pathways by which cells allow themselves to
overcome iatrogenic inhibition) [73, 74].
To date, much of the work on combination therapies
has focused on the use of verteporﬁn PDT in combina-
tion with VEGF blockade [73]. Preliminary results suggest
that this approach may reduce the number of treatments
required to render the CNV lesion quiescent—but at
the expense of achieving maximum visual gain. The 12-
month results of the DENALI study were recently reported.
In this phase IIIb study, patients receiving combination
therapy required fewer retreatments than those receiving
ranibizumab monotherapy (2.2 for the standard ﬂuence
group and 2.8 for the reduced ﬂuence group, compared with
7.6 additional retreatments in the ranibizumab monother-
apy group), but their mean visual acuity gain was less
(5.3 letters for the standard ﬂuence group and 4.4 letters
for the reduced ﬂuence group, compared with 8.1 let-
ters for the patients receiving ranibizumab monotherapy)
[75].
VEGF blockade is also being combined with macular
radiation therapy, either from an internal approach via
introduction of a radioactive probe via pars plana vitrec-
tomy, or from an external approach delivered through the
inferiorsclera[76].PreliminaryresultssuggestthatepiretinalJournal of Ophthalmology 7
intraocular radiation, in combination with ranibizumab,
may result in a reduced need for intravitreous injections
[77]. Caution is still required, particularly with regard to
potential ocular adverse eﬀects, and phase III clinical trials
are currently underway.
7.3. Other Anti-VEGF Therapies—VEGF Trap. Aﬂibercept
(VEGF Trap, Regeneron Pharmaceuticals, Tarrytown, NY)
is a fusion protein speciﬁcally designed to bind to all
isoforms of VEGF with a higher aﬃnity than either
bevacizumab or ranibizumab, thereby oﬀering a theoret-
ically longer interval between doses [78, 79]. The use of
intravitreous “VEGF Trap-Eye” (a formulation of VEGF
Trap for intraocular delivery) has recently been assessed
in two phase III clinical trials. In the North American
“View 1” trial, patients receiving 2.0mg of VEGF Trap-
Eye—every two months—gained an average of 7.9 letters
of visual acuity. Similarly, in the European “View 2” trial,
patients receiving 2.0mg of VEGF Trap-Eye—every two
months—gained an average of 8.9 letters of visual acuity
(http://www.regeneron.com/vegftrap eye.html).
7.4. Other Therapies. Since the revolutionary introduction
of bevacizumab and ranibizumab, much of the clinical
focus in neovascular AMD has been on the development
of optimal treatment regimens and use of combination
therapies. However, it is becoming increasingly clear that the
development and progression of CNV lesions occurs in the
context of a more slowly evolving, underlying disorder—
atrophic or “dry” AMD. It appears likely that, even with
early diagnosis and optimal treatment, the visual beneﬁts
achievable with anti-VEGF therapies will reach a plateau—
and,insomepatients,inexorablevisuallossmayoccur.Thus,
further visual gains among patients undergoing anti-VEGF
therapy may require novel treatment strategies that promote
RPE and photoreceptor survival rather than targeting CNV.
In this regard, a number of therapies now in development
for dry AMD, using neuroprotective, anti-inﬂammatory, and
visual-cycle targeted, strategies, may be of beneﬁt [75].
8. Conclusion
The introduction of anti-VEGF therapy was a massive ﬁrst
step in the successful treatment of neovascular AMD and is
likely to revolutionize the treatment of many other macular
disorders. However, while anti-VEGF therapy represents the
current “state of the art” in AMD therapeutics, this situation
is likely to change rapidly in the coming years.
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